SCHEDULE: Zenas BioPharma Stakeholder Updates Ownership

Leon O. Moulder, Jr. and associated entities report a combined 4.79% stake in Zenas BioPharma following recent share acquisitions.

Summary

• This filing is an amendment to a previous Schedule 13D, updating the beneficial ownership of Zenas BioPharma, Inc. common stock.
• Leon O. Moulder, Jr. directly holds 423,155 shares and has options for another 843,799 shares exercisable within 60 days.
• Tellus BioVentures, LLC, managed by Mr. Moulder, holds 1,726,039 shares.
• The Leon O. Moulder, Jr. Revocable Trust holds 36,928 shares.
• The total beneficial ownership reported by Mr. Moulder and associated entities is 3,029,921 shares, representing 4.79% of the class.
• Recent transactions include Mr. Moulder's purchase of 57,000 shares between February 2, 2026, and March 31, 2026, and Tellus BioVentures' purchase of 54,000 shares between March 30, 2026, and March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update on ownership stakes and recent transactions without new operational or financial performance data.

Positives

• Increased direct and indirect shareholding by a key stakeholder, indicating continued confidence or strategic interest.
• Recent open-market purchases by both Mr. Moulder and Tellus BioVentures demonstrate active engagement with the company's stock.
• The filing is an amendment, suggesting ongoing monitoring and reporting of ownership stakes, which is standard for significant investors.

Negatives

• No explicit negative financial or operational information is presented in this ownership filing.

Risks

• The filing does not explicitly mention risks. However, any investment in publicly traded securities carries inherent market risks.
• Potential for future changes in beneficial ownership, which could impact stock price and corporate strategy.

Future Outlook

The filing itself is an update on ownership and does not contain forward-looking statements or guidance from the company regarding its business operations or financial performance.

Management Comments

• Mr. Moulder is the Managing Member of Tellus and may be deemed to have sole voting and dispositive power over the shares held by Tellus.
• Mr. Moulder is a trustee of the Trust and may be deemed to have sole voting and dispositive power over the shares held by the Trust.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes in public companies, particularly in the biotechnology sector where strategic stakes can be influential.

Stakeholder Impact

• Shareholders: Increased stake by a significant investor may signal confidence or potential for future strategic actions.
• Management: The filing clarifies the beneficial ownership structure, which is important for corporate governance and transparency.

Next Steps

• Continued monitoring of Zenas BioPharma's stock performance and any further ownership filings.
• Review of Zenas BioPharma's operational and financial reports for business updates.

Key Dates

Keywords

Schedule 13D, Zenas BioPharma, Leon O. Moulder, Jr., Tellus BioVentures, Beneficial Ownership, Stock Acquisition, SEC Filing, Amendment, Common Stock, Options